AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) released its earnings results on Tuesday. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.15, Fidelity Earnings reports. AEterna Zentaris had a negative net margin of 666.76% and a negative return on equity of 328.95%. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.20 million.

NASDAQ AEZS traded down $0.41 on Wednesday, reaching $2.08. 2,700 shares of the stock were exchanged, compared to its average volume of 227,575. AEterna Zentaris has a one year low of $1.29 and a one year high of $5.57. The firm has a market cap of $40.94 million, a price-to-earnings ratio of 8.64 and a beta of 1.26. The firm’s 50-day moving average price is $2.60.

A number of equities research analysts have commented on AEZS shares. ValuEngine cut shares of AEterna Zentaris from a “buy” rating to a “hold” rating in a research note on Tuesday, June 11th. TheStreet cut shares of AEterna Zentaris from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $3.17.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: What is a balanced fund?

Earnings History for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.